S100A1: a novel inotropic regulator of cardiac performance. Transition from molecular physiology to pathophysiological relevance.
about
Model-specific selection of molecular targets for heart failure gene therapyCardiovascular gene therapy for myocardial infarctionGene therapy targets in heart failure: the path to translationPost-translational S-Nitrosylation Is an Endogenous Factor Fine Tuning the Properties of Human S100A1 ProteinS100A1 is released from ischemic cardiomyocytes and signals myocardial damage via Toll-like receptor 4S100A1 in human heart failure: lack of recovery following left ventricular assist device supportS100A1 and calmodulin regulation of ryanodine receptor in striated muscleS100A1 in cardiovascular health and disease: closing the gap between basic science and clinical therapyS100A1: Structure, Function, and Therapeutic PotentialS100A1: a multifaceted therapeutic target in cardiovascular diseaseAugmentation of Cav1 channel current and action potential duration after uptake of S100A1 in sympathetic ganglion neurons.Heart failure management: the present and the future.S100A1: a regulator of striated muscle sarcoplasmic reticulum Ca2+ handling, sarcomeric, and mitochondrial functionTargeted gene-silencing reveals the functional significance of myocardin signaling in the failing heartS100A1 promotes action potential-initiated calcium release flux and force production in skeletal muscleS100 calcium binding proteins and ion channelsLiquid jet delivery method featuring S100A1 gene therapy in the rodent model following acute myocardial infarction.Immunohistochemical detection of S100A1 in the postmortem diagnosis of acute myocardial infarction.Gene therapy in heart failure.Functions of S100 proteins.S100A1 transgenic treatment of acute heart failure causes proteomic changes in rats.Designing heart performance by gene transfer.Gene therapy to treat cardiovascular disease.The rapidly expanding CREC protein family: members, localization, function, and role in disease.Factors controlling the activity of the SERCA2a pump in the normal and failing heart.Sarcoplasmic reticulum Ca(2+) ATPase as a therapeutic target for heart failure.Induction of microRNA-138 by pro-inflammatory cytokines causes endothelial cell dysfunction.Gene and cytokine therapy for heart failure: molecular mechanisms in the improvement of cardiac function.Gene therapy for heart disease: molecular targets, vectors and modes of delivery to myocardium.Desmin in muscle and associated diseases: beyond the structural function.Targeting danger-associated molecular patterns after myocardial infarction.Cardiac Overexpression of S100A6 Attenuates Cardiomyocyte Apoptosis and Reduces Infarct Size After Myocardial Ischemia-Reperfusion.Ca(2+)-binding proteins in dogs with heart failure: effects of cardiac contractility modulation electrical signals.Lack of S100A1 in mice confers a gender-dependent hypertensive phenotype and increased mortality after myocardial infarction.S100A1: a physiological modulator of RYR1, Ca2+ release, and contractility in skeletal muscle. Focus on "S100A1 promotes action potential-initiated calcium release flux and force production in skeletal muscle".The Qgamma component of intra-membrane charge movement is present in mammalian muscle fibres, but suppressed in the absence of S100A1.Gene Therapy in Heart Failure.Gene profiling of left ventricle eccentric hypertrophy in aortic regurgitation in rats: rationale for targeting the beta-adrenergic and renin-angiotensin systems.X-ray crystal structure of human calcium-bound S100A1.Functional evidence for an active role of B-type natriuretic peptide in cardiac remodelling and pro-arrhythmogenicity.
P2860
Q26823061-251A8439-5326-42D8-BAC0-F34935A232FEQ27014770-A9825721-D54D-4670-BBF3-679B688273B8Q27022444-5439C2E0-2768-4F62-8F19-DE8C9A3401BCQ27673395-658929A4-27D7-41DB-893E-B84CD666B940Q28240188-545F9A52-2D80-491F-B9CA-BCD8A692BB94Q28240412-3DA3ECE7-0824-401B-BC43-52092E873203Q28243947-1AB41E06-BBC7-4E48-A254-88918E086ACAQ28249115-BC798537-D114-42DA-B3E6-47015935BC52Q28263662-5D23E69F-405D-4DB0-9ED1-DBE419D32909Q28288362-17D38940-EDB4-45B1-ABD6-B59C312B569FQ28580012-D1F3B7B3-D289-451D-823A-89CD8A5F6AD7Q33605156-664B5FE3-5C03-4BAB-8693-4DA24A4D8354Q33757903-4D58942F-9E4C-49BE-8C72-6F6D91FAE3F5Q34058563-8C399CD0-0824-474D-8F04-88501F986CDDQ34304947-ED6DD2C4-51E4-4798-B651-651E8C32374CQ35911792-E433A881-976C-46D7-873A-15D41DFB64FDQ36547398-8747E7CE-3A02-4C22-A352-565628A3F5D4Q36874312-0BF05CC1-74C9-442C-8C06-08CC97D14EC0Q36944623-56F8D0EC-53B8-4609-8F6D-669330C204ACQ37001259-E49F40C3-FC7C-4076-8BF5-F3AF1BC9FF76Q37082922-4D7E3527-81EA-4017-A817-EAE21268EB2BQ37299072-A502CE9B-D365-4FFF-A2E4-F95C42B747A6Q37310450-16BEC75F-A15C-45F3-B160-16C74A704B14Q37406105-52BA07D9-4F0F-46AF-9E88-AD65214158B1Q37630987-5F33CE45-C6B6-41BC-8D39-ADB99F6F7EC2Q37676218-F7037D6E-3F08-4FF4-9F16-15837E5824DEQ37683440-9FB4D6BD-9242-4F9F-8A16-372A5F41484CQ38025012-57FBC19F-F4D3-47D7-8550-7374E7DF2D4CQ38132253-1C2A053C-6D80-46E2-A146-4B713AC74C35Q38263986-1662705D-EFDC-4677-A11D-350767147645Q38595544-EA3C7B44-C0F3-403C-A535-BF05313F2DFBQ41102519-26DA7CB3-5112-4007-A3C6-FBA411F16F2FQ41775044-BEFDEF10-8EF1-430F-922F-5B1A0C410B49Q42450906-CDFF39B3-2C3A-438A-8D51-580B3F6B05E3Q42920118-62DF4A1D-7B34-4554-A241-B5461D321D97Q43299306-A7CB51CE-1148-466F-851A-B581B0F3618EQ45861410-0A0E58D5-8FF7-4CED-B1E4-D992BE6AF6ACQ46181261-F5E786A7-EABC-4233-9F86-B610A1549F02Q48234052-7ABFFCD5-B341-4E9C-B842-BD77E0D926BDQ48498411-2EC3AD19-B850-423E-B301-CB7BE2500798
P2860
S100A1: a novel inotropic regulator of cardiac performance. Transition from molecular physiology to pathophysiological relevance.
description
2007 nî lūn-bûn
@nan
2007年の論文
@ja
2007年論文
@yue
2007年論文
@zh-hant
2007年論文
@zh-hk
2007年論文
@zh-mo
2007年論文
@zh-tw
2007年论文
@wuu
2007年论文
@zh
2007年论文
@zh-cn
name
S100A1: a novel inotropic regu ...... pathophysiological relevance.
@ast
S100A1: a novel inotropic regu ...... pathophysiological relevance.
@en
type
label
S100A1: a novel inotropic regu ...... pathophysiological relevance.
@ast
S100A1: a novel inotropic regu ...... pathophysiological relevance.
@en
prefLabel
S100A1: a novel inotropic regu ...... pathophysiological relevance.
@ast
S100A1: a novel inotropic regu ...... pathophysiological relevance.
@en
P2093
P2860
P1476
S100A1: a novel inotropic regu ...... pathophysiological relevance.
@en
P2093
Andrew Remppis
Hugo A Katus
Patrick Most
Sven T Pleger
Walter J Koch
P2860
P304
P356
10.1152/AJPREGU.00075.2007
P577
2007-04-25T00:00:00Z